TheraSphere™ Y-90 Glass Microspheres: The LEGACY Study

139 views
November 13, 2020

The Legacy Study is a robust multicenter study confirming TheraSphere™ as a neoadjuvant or standalone therapy in treating HCC.

Click here to view the presentation which provides background on the use of TheraSphere™ Y-90 glass microspheres to treat HCC, discusses results of the LEGACY study and recently published studies using Y-90 glass microspheres.

Comments 0
Login to view comments. Click here to Login